(177)Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer

There is a clinically unmet need for effective treatments for triple-negative breast cancer (TNBC), as it remains the most aggressive subtype of breast cancer. Herein, we demonstrate a promising strategy using a tumor-targeting alkylphosphocholine (NM600) for targeted radionuclide therapy of TNBC. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez, Reinier, Grudzinski, Joseph J., Aluicio-Sarduy, Eduardo, Massey, Christopher F., Pinchuk, Anatoly N., Bitton, Ariana N., Patel, Ravi, Zhang, Ray, Rao, Aakarsha V., Iyer, Gopal, Engle, Jonathan W., Weichert, Jamey P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2020
Materias:
Radionuclide Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413241/
https://www.ncbi.nlm.nih.gov/pubmed/31862799
http://dx.doi.org/10.2967/jnumed.119.236265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413241/
https://www.ncbi.nlm.nih.gov/pubmed/31862799
http://dx.doi.org/10.2967/jnumed.119.236265

Ejemplares similares